Envista Holdings Co. (NYSE:NVST) – Equities researchers at William Blair lowered their Q1 2022 EPS estimates for Envista in a research note issued to investors on Wednesday, September 8th. William Blair analyst J. Kreger now forecasts that the company will earn $0.49 per share for the quarter, down from their prior estimate of $0.56. William Blair also issued estimates for Envista’s Q4 2022 earnings at $0.47 EPS, FY2024 earnings at $2.12 EPS and FY2025 earnings at $2.24 EPS. Envista (NYSE:NVST) last released its earnings results on Tuesday, August 3rd. The company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.09. Envista had a net margin of 10.84% and a return on equity of 9.72%. The business had revenue of $740.10 million during the quarter, compared to analysts’ expectations of $705.75 million.
NVST has been the subject of several other research reports. TheStreet upgraded shares of Envista from a “d+” rating to a “c” rating in a research note on Thursday, May 13th. Piper Sandler raised their price target on shares of Envista from $45.00 to $47.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 4th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $43.67.
NYSE NVST opened at $43.17 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.85 and a current ratio of 1.12. The firm has a 50-day simple moving average of $42.04 and a 200 day simple moving average of $42.19. Envista has a twelve month low of $22.51 and a twelve month high of $46.52. The stock has a market cap of $6.96 billion, a PE ratio of 24.25, a PEG ratio of 0.80 and a beta of 1.93.
Institutional investors have recently modified their holdings of the stock. Sandler Capital Management acquired a new stake in shares of Envista in the first quarter valued at approximately $6,391,000. Prudential Financial Inc. increased its holdings in shares of Envista by 542.8% in the first quarter. Prudential Financial Inc. now owns 46,922 shares of the company’s stock valued at $1,914,000 after purchasing an additional 39,622 shares in the last quarter. BlackRock Inc. grew its holdings in Envista by 2.0% during the 1st quarter. BlackRock Inc. now owns 11,969,160 shares of the company’s stock worth $488,342,000 after acquiring an additional 231,443 shares during the period. Kore Private Wealth LLC grew its holdings in Envista by 8.8% during the 1st quarter. Kore Private Wealth LLC now owns 6,506 shares of the company’s stock worth $265,000 after acquiring an additional 524 shares during the period. Finally, Pura Vida Investments LLC grew its holdings in Envista by 53.1% during the 1st quarter. Pura Vida Investments LLC now owns 283,176 shares of the company’s stock worth $11,554,000 after acquiring an additional 98,176 shares during the period.
In other news, insider Curt W. Bludworth sold 14,654 shares of Envista stock in a transaction that occurred on Friday, June 11th. The shares were sold at an average price of $44.00, for a total value of $644,776.00. Following the completion of the transaction, the insider now owns 78,212 shares in the company, valued at $3,441,328. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Mark E. Nance sold 14,263 shares of Envista stock in a transaction that occurred on Friday, June 11th. The shares were sold at an average price of $44.05, for a total transaction of $628,285.15. Following the completion of the transaction, the general counsel now owns 34,327 shares of the company’s stock, valued at approximately $1,512,104.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,001 shares of company stock valued at $1,786,341. Corporate insiders own 0.82% of the company’s stock.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
See Also: What is intrinsic value?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Envista, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Envista wasn’t on the list.
While Envista currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.